|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00394823 |
The purpose of this study is to assess the impact of supportive measures on the drug adherence of patients with essential hypertension
Condition | Intervention | Phase |
Hypertension |
Behavioral: Set of supportive tools/measures vs. standard care |
Phase III |
MedlinePlus related topics: | High Blood Pressure |
ChemIDplus related topics: | Valsartan |
Study Type: | Interventional |
Study Design: | Other, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open-Label, Multicentric Parallel Group Study to Assess the Impact of Supportive Measures on the Drug Adherence of Patients With Essential Hypertension Treated With Valsartan or Valsartan Plus HCTZ for 34 Weeks With or Without Respective Measures |
Estimated Enrollment: | 220 |
Study Start Date: | November 2005 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Study ID Numbers: | CVAL489ADE24 |
First Received: | October 31, 2006 |
Last Updated: | November 7, 2007 |
ClinicalTrials.gov Identifier: | NCT00394823 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|